Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841131 | 0.83 | OPRM1 (0.51) | OPRM1CACNA1GKCNH2DRD2SLC18A3 | |
| SCHEMBL6841698 | 0.82 | PTGDR2 (0.54) | OPRM1CACNA1GKCNH2DRD2MEN1 | |
| SCHEMBL6841708 | 0.81 | OPRM1 (0.52) | OPRM1CACNA1GKCNH2DRD2MEN1 | |
| SCHEMBL6843620 | 0.79 | OPRM1 (0.58) | OPRM1KCNH2OPRD1CHRM4CHRM3 | |
| SCHEMBL8603796 | 0.73 | OPRM1 (0.58) | OPRM1SLC18A3OPRD1HRH3 | |
| Hydrochloric Acid SCHEMBL8605242 | 0.71 | OPRM1 (0.56) | OPRM1KCNH2SLC18A3CHRM4CHRM3 | |
| SCHEMBL6841059 | 0.71 | OPRM1 (0.57) | OPRM1CACNA1GKCNH2DRD2MEN1 | |
| SCHEMBL6841120 | 0.70 | OPRM1 (0.52) | OPRM1CACNA1GKCNH2DRD2SLC18A3 | |
| Desmethylmoramide SCHEMBL2111155 | 0.69 | OPRM1 (0.68) | OPRM1KCNH2MEN1KMT2AOPRD1 | |
| SCHEMBL6841483 | 0.69 | OPRM1 (0.55) | OPRM1CACNA1GKCNH2DRD2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034104-A1 | 2,2-Diphenylbutanamide derivatives and medicines containing the same | SSP CO., LTD. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1325912-A1 | 2,2-DIPHENYLBUTANAMIDE DERIVATIVES AND MEDICINES CONTAINING THE SAME | SSP Co., Ltd. (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034104-A1 | 2,2-Diphenylbutanamide derivatives and medicines containing the same | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885CACNA1G 122/4885KCNH2 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.